nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—ABCG2—Dactinomycin—muscle cancer	0.149	0.204	CbGbCtD
Vismodegib—ABCG2—Vincristine—muscle cancer	0.0918	0.126	CbGbCtD
Vismodegib—ABCG2—Etoposide—muscle cancer	0.0841	0.115	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—muscle cancer	0.0574	0.0787	CbGbCtD
Vismodegib—ABCG2—Methotrexate—muscle cancer	0.0556	0.0762	CbGbCtD
Vismodegib—ABCB1—Dactinomycin—muscle cancer	0.0537	0.0737	CbGbCtD
Vismodegib—CYP2C8—Etoposide—muscle cancer	0.0448	0.0614	CbGbCtD
Vismodegib—ALB—Methotrexate—muscle cancer	0.0383	0.0525	CbGbCtD
Vismodegib—ABCB1—Vincristine—muscle cancer	0.0331	0.0454	CbGbCtD
Vismodegib—ABCB1—Etoposide—muscle cancer	0.0303	0.0416	CbGbCtD
Vismodegib—SHH—appendage—muscle cancer	0.0222	0.301	CbGeAlD
Vismodegib—ABCB1—Doxorubicin—muscle cancer	0.0207	0.0284	CbGbCtD
Vismodegib—ABCB1—Methotrexate—muscle cancer	0.02	0.0275	CbGbCtD
Vismodegib—CYP3A4—Vincristine—muscle cancer	0.0198	0.0272	CbGbCtD
Vismodegib—SHH—Glypican 3 network—PTCH1—muscle cancer	0.0187	0.125	CbGpPWpGaD
Vismodegib—CYP3A4—Etoposide—muscle cancer	0.0182	0.0249	CbGbCtD
Vismodegib—CYP3A4—Doxorubicin—muscle cancer	0.0124	0.017	CbGbCtD
Vismodegib—SHH—Hedgehog Signaling Pathway—PTCH1—muscle cancer	0.0107	0.072	CbGpPWpGaD
Vismodegib—SMO—Hedgehog Signaling Pathway—PTCH1—muscle cancer	0.0102	0.0682	CbGpPWpGaD
Vismodegib—SHH—Signaling events mediated by the Hedgehog family—PTCH1—muscle cancer	0.00804	0.0539	CbGpPWpGaD
Vismodegib—SMO—Signaling events mediated by the Hedgehog family—PTCH1—muscle cancer	0.00762	0.0511	CbGpPWpGaD
Vismodegib—SHH—embryo—muscle cancer	0.00736	0.0998	CbGeAlD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—TP63—muscle cancer	0.00663	0.0444	CbGpPWpGaD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—TP63—muscle cancer	0.00628	0.0421	CbGpPWpGaD
Vismodegib—SHH—renal system—muscle cancer	0.00557	0.0755	CbGeAlD
Vismodegib—SHH—Validated transcriptional targets of TAp63 isoforms—TP63—muscle cancer	0.00542	0.0363	CbGpPWpGaD
Vismodegib—SMO—embryo—muscle cancer	0.00515	0.0698	CbGeAlD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—PTCH1—muscle cancer	0.00497	0.0333	CbGpPWpGaD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—PTCH1—muscle cancer	0.00471	0.0315	CbGpPWpGaD
Vismodegib—SHH—Hedgehog signaling events mediated by Gli proteins—PTCH1—muscle cancer	0.00446	0.0299	CbGpPWpGaD
Vismodegib—SHH—Ectoderm Differentiation—PAX3—muscle cancer	0.0044	0.0295	CbGpPWpGaD
Vismodegib—Sorafenib—KIT—muscle cancer	0.00424	0.564	CrCbGaD
Vismodegib—SMO—Hedgehog signaling events mediated by Gli proteins—PTCH1—muscle cancer	0.00423	0.0283	CbGpPWpGaD
Vismodegib—SHH—bone marrow—muscle cancer	0.00421	0.0571	CbGeAlD
Vismodegib—SHH—head—muscle cancer	0.00373	0.0505	CbGeAlD
Vismodegib—SMO—cardiac atrium—muscle cancer	0.00349	0.0473	CbGeAlD
Vismodegib—SMO—tendon—muscle cancer	0.00304	0.0412	CbGeAlD
Vismodegib—SMO—vagina—muscle cancer	0.00282	0.0383	CbGeAlD
Vismodegib—SHH—Ectoderm Differentiation—DMD—muscle cancer	0.0028	0.0187	CbGpPWpGaD
Vismodegib—SHH—Class B/2 (Secretin family receptors)—PTCH1—muscle cancer	0.00277	0.0186	CbGpPWpGaD
Vismodegib—SMO—Class B/2 (Secretin family receptors)—PTCH1—muscle cancer	0.00263	0.0176	CbGpPWpGaD
Vismodegib—SMO—head—muscle cancer	0.00261	0.0354	CbGeAlD
Vismodegib—SMO—testis—muscle cancer	0.00252	0.0342	CbGeAlD
Vismodegib—SMO—Hedgehog 'off' state—PTCH1—muscle cancer	0.00239	0.016	CbGpPWpGaD
Vismodegib—SHH—Signaling by Hedgehog—PTCH1—muscle cancer	0.00225	0.0151	CbGpPWpGaD
Vismodegib—SHH—Differentiation Pathway—KIT—muscle cancer	0.00216	0.0145	CbGpPWpGaD
Vismodegib—SMO—GPCRs, Other—CNR1—muscle cancer	0.00214	0.0143	CbGpPWpGaD
Vismodegib—SMO—Signaling by Hedgehog—PTCH1—muscle cancer	0.00213	0.0143	CbGpPWpGaD
Vismodegib—Etoricoxib—PTGS2—muscle cancer	0.00206	0.275	CrCbGaD
Vismodegib—Azotaemia—Vincristine—muscle cancer	0.00193	0.0479	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.00174	0.0116	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.00165	0.011	CbGpPWpGaD
Vismodegib—SHH—Validated transcriptional targets of TAp63 isoforms—CDKN2A—muscle cancer	0.0016	0.0107	CbGpPWpGaD
Vismodegib—SHH—Validated transcriptional targets of TAp63 isoforms—MDM2—muscle cancer	0.00155	0.0104	CbGpPWpGaD
Vismodegib—SHH—Heart Development—VEGFA—muscle cancer	0.00138	0.00928	CbGpPWpGaD
Vismodegib—SHH—Differentiation Pathway—VEGFA—muscle cancer	0.00129	0.00865	CbGpPWpGaD
Vismodegib—ORM1—bone marrow—muscle cancer	0.00129	0.0175	CbGeAlD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.00127	0.00852	CbGpPWpGaD
Vismodegib—Sulfasalazine—PTGS2—muscle cancer	0.00122	0.162	CrCbGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.0012	0.00807	CbGpPWpGaD
Vismodegib—Musculoskeletal chest pain—Doxorubicin—muscle cancer	0.00111	0.0276	CcSEcCtD
Vismodegib—CYP2C8—renal system—muscle cancer	0.00105	0.0142	CbGeAlD
Vismodegib—Musculoskeletal pain—Vincristine—muscle cancer	0.00104	0.0258	CcSEcCtD
Vismodegib—ALB—testis—muscle cancer	0.000965	0.0131	CbGeAlD
Vismodegib—Azotaemia—Methotrexate—muscle cancer	0.000936	0.0232	CcSEcCtD
Vismodegib—CYP2C19—vagina—muscle cancer	0.000871	0.0118	CbGeAlD
Vismodegib—Phosphatase alkaline increased—Etoposide—muscle cancer	0.000833	0.0207	CcSEcCtD
Vismodegib—ABCG2—bone marrow—muscle cancer	0.000772	0.0105	CbGeAlD
Vismodegib—CYP2C8—vagina—muscle cancer	0.00076	0.0103	CbGeAlD
Vismodegib—SHH—GPCR ligand binding—PTCH1—muscle cancer	0.000758	0.00508	CbGpPWpGaD
Vismodegib—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.000752	0.0187	CcSEcCtD
Vismodegib—Hyponatraemia—Vincristine—muscle cancer	0.000749	0.0186	CcSEcCtD
Vismodegib—Pain in extremity—Vincristine—muscle cancer	0.000746	0.0185	CcSEcCtD
Vismodegib—ABCG2—vagina—muscle cancer	0.000739	0.01	CbGeAlD
Vismodegib—SMO—GPCR ligand binding—PTCH1—muscle cancer	0.000719	0.00482	CbGpPWpGaD
Vismodegib—CYP3A4—renal system—muscle cancer	0.000711	0.00964	CbGeAlD
Vismodegib—Blood alkaline phosphatase increased—Etoposide—muscle cancer	0.000695	0.0172	CcSEcCtD
Vismodegib—Dehydration—Vincristine—muscle cancer	0.000694	0.0172	CcSEcCtD
Vismodegib—CYP2C8—testis—muscle cancer	0.000678	0.0092	CbGeAlD
Vismodegib—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.000672	0.0167	CcSEcCtD
Vismodegib—ABCB1—embryo—muscle cancer	0.000665	0.00901	CbGeAlD
Vismodegib—ABCG2—testis—muscle cancer	0.00066	0.00894	CbGeAlD
Vismodegib—SHH—GPCR ligand binding—CNR1—muscle cancer	0.00064	0.00429	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CNR1—muscle cancer	0.000607	0.00406	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KIDINS220—muscle cancer	0.000584	0.00391	CbGpPWpGaD
Vismodegib—Weight decreased—Vincristine—muscle cancer	0.000583	0.0145	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000563	0.00377	CbGpPWpGaD
Vismodegib—CYP2C19—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000559	0.00375	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KIDINS220—muscle cancer	0.000554	0.00371	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000543	0.00364	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000534	0.00358	CbGpPWpGaD
Vismodegib—Ageusia—Doxorubicin—muscle cancer	0.000533	0.0132	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Methotrexate—muscle cancer	0.000527	0.0131	CcSEcCtD
Vismodegib—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000517	0.00346	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000515	0.00345	CbGpPWpGaD
Vismodegib—Alopecia—Dactinomycin—muscle cancer	0.00051	0.0127	CcSEcCtD
Vismodegib—Connective tissue disorder—Vincristine—muscle cancer	0.000507	0.0126	CcSEcCtD
Vismodegib—Neoplasm malignant—Doxorubicin—muscle cancer	0.000506	0.0126	CcSEcCtD
Vismodegib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000505	0.00339	CbGpPWpGaD
Vismodegib—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000504	0.00338	CbGpPWpGaD
Vismodegib—ABCB1—renal system—muscle cancer	0.000503	0.00682	CbGeAlD
Vismodegib—Amenorrhoea—Doxorubicin—muscle cancer	0.000491	0.0122	CcSEcCtD
Vismodegib—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000471	0.00316	CbGpPWpGaD
Vismodegib—Alopecia—Vincristine—muscle cancer	0.000456	0.0113	CcSEcCtD
Vismodegib—Musculoskeletal pain—Doxorubicin—muscle cancer	0.000437	0.0109	CcSEcCtD
Vismodegib—Back pain—Vincristine—muscle cancer	0.000435	0.0108	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.000432	0.0107	CcSEcCtD
Vismodegib—Myalgia—Dactinomycin—muscle cancer	0.000428	0.0106	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000428	0.00287	CbGpPWpGaD
Vismodegib—Blood urea increased—Doxorubicin—muscle cancer	0.000408	0.0101	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000406	0.00272	CbGpPWpGaD
Vismodegib—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	0.000405	0.00271	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—PTCH1—muscle cancer	0.000389	0.00261	CbGpPWpGaD
Vismodegib—Myalgia—Vincristine—muscle cancer	0.000382	0.0095	CcSEcCtD
Vismodegib—ABCB1—bone marrow—muscle cancer	0.000381	0.00516	CbGeAlD
Vismodegib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000374	0.00928	CcSEcCtD
Vismodegib—Alopecia—Etoposide—muscle cancer	0.000369	0.00917	CcSEcCtD
Vismodegib—SMO—Signaling by GPCR—PTCH1—muscle cancer	0.000369	0.00247	CbGpPWpGaD
Vismodegib—ABCB1—vagina—muscle cancer	0.000365	0.00494	CbGeAlD
Vismodegib—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.00036	0.00895	CcSEcCtD
Vismodegib—Nervous system disorder—Vincristine—muscle cancer	0.00036	0.00893	CcSEcCtD
Vismodegib—Decreased appetite—Dactinomycin—muscle cancer	0.000357	0.00886	CcSEcCtD
Vismodegib—Dysgeusia—Etoposide—muscle cancer	0.000356	0.00885	CcSEcCtD
Vismodegib—Fatigue—Dactinomycin—muscle cancer	0.000354	0.00878	CcSEcCtD
Vismodegib—Back pain—Etoposide—muscle cancer	0.000352	0.00874	CcSEcCtD
Vismodegib—Pain—Dactinomycin—muscle cancer	0.000351	0.00871	CcSEcCtD
Vismodegib—Muscle spasms—Etoposide—muscle cancer	0.00035	0.00869	CcSEcCtD
Vismodegib—SHH—Disease—ENO2—muscle cancer	0.000346	0.00232	CbGpPWpGaD
Vismodegib—ABCB1—head—muscle cancer	0.000337	0.00457	CbGeAlD
Vismodegib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000336	0.00833	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000334	0.00829	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—CNR1—muscle cancer	0.000328	0.0022	CbGpPWpGaD
Vismodegib—Breast disorder—Methotrexate—muscle cancer	0.000327	0.00812	CcSEcCtD
Vismodegib—ABCB1—testis—muscle cancer	0.000325	0.00441	CbGeAlD
Vismodegib—Abdominal pain—Dactinomycin—muscle cancer	0.000324	0.00805	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000323	0.00217	CbGpPWpGaD
Vismodegib—Decreased appetite—Vincristine—muscle cancer	0.000319	0.00791	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000317	0.00786	CcSEcCtD
Vismodegib—Fatigue—Vincristine—muscle cancer	0.000316	0.00785	CcSEcCtD
Vismodegib—Hyponatraemia—Doxorubicin—muscle cancer	0.000315	0.00781	CcSEcCtD
Vismodegib—SHH—Disease—HMGA1—muscle cancer	0.000315	0.00211	CbGpPWpGaD
Vismodegib—Pain—Vincristine—muscle cancer	0.000314	0.00778	CcSEcCtD
Vismodegib—Constipation—Vincristine—muscle cancer	0.000314	0.00778	CcSEcCtD
Vismodegib—Pain in extremity—Doxorubicin—muscle cancer	0.000313	0.00778	CcSEcCtD
Vismodegib—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	0.000313	0.0021	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CNR1—muscle cancer	0.000311	0.00209	CbGpPWpGaD
Vismodegib—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000311	0.00208	CbGpPWpGaD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000308	0.00764	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000306	0.00205	CbGpPWpGaD
Vismodegib—ALB—Platelet degranulation—IGF2—muscle cancer	0.000301	0.00201	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Vincristine—muscle cancer	0.0003	0.00744	CcSEcCtD
Vismodegib—Asthenia—Dactinomycin—muscle cancer	0.000294	0.00731	CcSEcCtD
Vismodegib—Dehydration—Doxorubicin—muscle cancer	0.000291	0.00724	CcSEcCtD
Vismodegib—Abdominal pain—Vincristine—muscle cancer	0.00029	0.0072	CcSEcCtD
Vismodegib—Skin disorder—Etoposide—muscle cancer	0.000288	0.00716	CcSEcCtD
Vismodegib—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.000286	0.00192	CbGpPWpGaD
Vismodegib—Abdominal pain upper—Doxorubicin—muscle cancer	0.000286	0.00711	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—muscle cancer	0.000285	0.00708	CcSEcCtD
Vismodegib—Breast disorder—Doxorubicin—muscle cancer	0.000283	0.00703	CcSEcCtD
Vismodegib—SHH—Disease—FOXO4—muscle cancer	0.000282	0.00189	CbGpPWpGaD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000282	0.00701	CcSEcCtD
Vismodegib—Diarrhoea—Dactinomycin—muscle cancer	0.000281	0.00697	CcSEcCtD
Vismodegib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000273	0.00183	CbGpPWpGaD
Vismodegib—Asthenia—Vincristine—muscle cancer	0.000263	0.00653	CcSEcCtD
Vismodegib—Vomiting—Dactinomycin—muscle cancer	0.000261	0.00648	CcSEcCtD
Vismodegib—Rash—Dactinomycin—muscle cancer	0.000259	0.00642	CcSEcCtD
Vismodegib—Decreased appetite—Etoposide—muscle cancer	0.000258	0.00641	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000256	0.00637	CcSEcCtD
Vismodegib—Fatigue—Etoposide—muscle cancer	0.000256	0.00636	CcSEcCtD
Vismodegib—Constipation—Etoposide—muscle cancer	0.000254	0.00631	CcSEcCtD
Vismodegib—Pain—Etoposide—muscle cancer	0.000254	0.00631	CcSEcCtD
Vismodegib—Diarrhoea—Vincristine—muscle cancer	0.000251	0.00623	CcSEcCtD
Vismodegib—Weight decreased—Doxorubicin—muscle cancer	0.000245	0.00608	CcSEcCtD
Vismodegib—Nausea—Dactinomycin—muscle cancer	0.000244	0.00605	CcSEcCtD
Vismodegib—Gastrointestinal pain—Etoposide—muscle cancer	0.000243	0.00603	CcSEcCtD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000238	0.0016	CbGpPWpGaD
Vismodegib—Abdominal pain—Etoposide—muscle cancer	0.000235	0.00583	CcSEcCtD
Vismodegib—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000234	0.00157	CbGpPWpGaD
Vismodegib—Vomiting—Vincristine—muscle cancer	0.000233	0.00579	CcSEcCtD
Vismodegib—Rash—Vincristine—muscle cancer	0.000231	0.00574	CcSEcCtD
Vismodegib—Dermatitis—Vincristine—muscle cancer	0.000231	0.00573	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—PTCH1—muscle cancer	0.00023	0.00154	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000224	0.0015	CbGpPWpGaD
Vismodegib—Alopecia—Methotrexate—muscle cancer	0.000221	0.00549	CcSEcCtD
Vismodegib—Malnutrition—Methotrexate—muscle cancer	0.000218	0.00541	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—PTCH1—muscle cancer	0.000218	0.00146	CbGpPWpGaD
Vismodegib—Nausea—Vincristine—muscle cancer	0.000218	0.00541	CcSEcCtD
Vismodegib—Dysgeusia—Methotrexate—muscle cancer	0.000213	0.0053	CcSEcCtD
Vismodegib—Asthenia—Etoposide—muscle cancer	0.000213	0.00529	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—muscle cancer	0.000213	0.00529	CcSEcCtD
Vismodegib—Back pain—Methotrexate—muscle cancer	0.000211	0.00524	CcSEcCtD
Vismodegib—Pruritus—Etoposide—muscle cancer	0.00021	0.00522	CcSEcCtD
Vismodegib—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000209	0.0014	CbGpPWpGaD
Vismodegib—SHH—Disease—FOXO1—muscle cancer	0.000208	0.0014	CbGpPWpGaD
Vismodegib—Diarrhoea—Etoposide—muscle cancer	0.000203	0.00505	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—FOXO4—muscle cancer	0.000198	0.00132	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CNR1—muscle cancer	0.000194	0.0013	CbGpPWpGaD
Vismodegib—Alopecia—Doxorubicin—muscle cancer	0.000192	0.00476	CcSEcCtD
Vismodegib—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000191	0.00128	CbGpPWpGaD
Vismodegib—Vomiting—Etoposide—muscle cancer	0.000189	0.00469	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—muscle cancer	0.000189	0.00469	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—FOXO4—muscle cancer	0.000187	0.00126	CbGpPWpGaD
Vismodegib—Rash—Etoposide—muscle cancer	0.000187	0.00465	CcSEcCtD
Vismodegib—Dermatitis—Etoposide—muscle cancer	0.000187	0.00465	CcSEcCtD
Vismodegib—Arthralgia—Methotrexate—muscle cancer	0.000186	0.00461	CcSEcCtD
Vismodegib—Myalgia—Methotrexate—muscle cancer	0.000186	0.00461	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—muscle cancer	0.000185	0.00459	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000184	0.00458	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—CNR1—muscle cancer	0.000184	0.00123	CbGpPWpGaD
Vismodegib—Back pain—Doxorubicin—muscle cancer	0.000183	0.00453	CcSEcCtD
Vismodegib—Muscle spasms—Doxorubicin—muscle cancer	0.000181	0.00451	CcSEcCtD
Vismodegib—Nausea—Etoposide—muscle cancer	0.000176	0.00438	CcSEcCtD
Vismodegib—Nervous system disorder—Methotrexate—muscle cancer	0.000174	0.00433	CcSEcCtD
Vismodegib—Skin disorder—Methotrexate—muscle cancer	0.000173	0.00429	CcSEcCtD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000164	0.0011	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000162	0.00402	CcSEcCtD
Vismodegib—Myalgia—Doxorubicin—muscle cancer	0.000161	0.00399	CcSEcCtD
Vismodegib—Arthralgia—Doxorubicin—muscle cancer	0.000161	0.00399	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00016	0.00396	CcSEcCtD
Vismodegib—SHH—Disease—KIT—muscle cancer	0.000159	0.00106	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IGF2—muscle cancer	0.000159	0.00106	CbGpPWpGaD
Vismodegib—Dyspepsia—Methotrexate—muscle cancer	0.000157	0.00389	CcSEcCtD
Vismodegib—Decreased appetite—Methotrexate—muscle cancer	0.000155	0.00384	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000154	0.00381	CcSEcCtD
Vismodegib—Fatigue—Methotrexate—muscle cancer	0.000153	0.00381	CcSEcCtD
Vismodegib—Pain—Methotrexate—muscle cancer	0.000152	0.00378	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—muscle cancer	0.000151	0.00375	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—IGF2—muscle cancer	0.00015	0.00101	CbGpPWpGaD
Vismodegib—Skin disorder—Doxorubicin—muscle cancer	0.00015	0.00372	CcSEcCtD
Vismodegib—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	0.000148	0.000993	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—FOXO1—muscle cancer	0.000146	0.000978	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Methotrexate—muscle cancer	0.000145	0.00361	CcSEcCtD
Vismodegib—ALB—Hemostasis—ANGPT2—muscle cancer	0.000141	0.000947	CbGpPWpGaD
Vismodegib—Abdominal pain—Methotrexate—muscle cancer	0.000141	0.00349	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00014	0.00348	CcSEcCtD
Vismodegib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000139	0.000934	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—FOXO1—muscle cancer	0.000138	0.000927	CbGpPWpGaD
Vismodegib—Dyspepsia—Doxorubicin—muscle cancer	0.000136	0.00337	CcSEcCtD
Vismodegib—ABCG2—Metabolism—FH—muscle cancer	0.000134	0.000897	CbGpPWpGaD
Vismodegib—Decreased appetite—Doxorubicin—muscle cancer	0.000134	0.00332	CcSEcCtD
Vismodegib—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000133	0.000893	CbGpPWpGaD
Vismodegib—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000133	0.0033	CcSEcCtD
Vismodegib—Fatigue—Doxorubicin—muscle cancer	0.000133	0.0033	CcSEcCtD
Vismodegib—Pain—Doxorubicin—muscle cancer	0.000132	0.00327	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—muscle cancer	0.000132	0.00327	CcSEcCtD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000129	0.000863	CbGpPWpGaD
Vismodegib—Asthenia—Methotrexate—muscle cancer	0.000128	0.00317	CcSEcCtD
Vismodegib—ALB—Platelet degranulation—VEGFA—muscle cancer	0.000126	0.000844	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000126	0.00313	CcSEcCtD
Vismodegib—Pruritus—Methotrexate—muscle cancer	0.000126	0.00312	CcSEcCtD
Vismodegib—SHH—Disease—MDM2—muscle cancer	0.000125	0.000838	CbGpPWpGaD
Vismodegib—Abdominal pain—Doxorubicin—muscle cancer	0.000122	0.00302	CcSEcCtD
Vismodegib—Diarrhoea—Methotrexate—muscle cancer	0.000122	0.00302	CcSEcCtD
Vismodegib—SHH—Disease—PTGS2—muscle cancer	0.000121	0.000808	CbGpPWpGaD
Vismodegib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	0.00012	0.000804	CbGpPWpGaD
Vismodegib—Vomiting—Methotrexate—muscle cancer	0.000113	0.00281	CcSEcCtD
Vismodegib—Rash—Methotrexate—muscle cancer	0.000112	0.00278	CcSEcCtD
Vismodegib—Dermatitis—Methotrexate—muscle cancer	0.000112	0.00278	CcSEcCtD
Vismodegib—ABCB1—Allograft Rejection—VEGFA—muscle cancer	0.000112	0.000747	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KIT—muscle cancer	0.000111	0.000745	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—TP53—muscle cancer	0.000111	0.000744	CbGpPWpGaD
Vismodegib—Asthenia—Doxorubicin—muscle cancer	0.000111	0.00274	CcSEcCtD
Vismodegib—Pruritus—Doxorubicin—muscle cancer	0.000109	0.00271	CcSEcCtD
Vismodegib—Nausea—Methotrexate—muscle cancer	0.000106	0.00262	CcSEcCtD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000105	0.000707	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KIT—muscle cancer	0.000105	0.000706	CbGpPWpGaD
Vismodegib—Diarrhoea—Doxorubicin—muscle cancer	0.000105	0.00262	CcSEcCtD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000105	0.000703	CbGpPWpGaD
Vismodegib—Vomiting—Doxorubicin—muscle cancer	9.79e-05	0.00243	CcSEcCtD
Vismodegib—Rash—Doxorubicin—muscle cancer	9.71e-05	0.00241	CcSEcCtD
Vismodegib—Dermatitis—Doxorubicin—muscle cancer	9.7e-05	0.00241	CcSEcCtD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	9.41e-05	0.000631	CbGpPWpGaD
Vismodegib—Nausea—Doxorubicin—muscle cancer	9.15e-05	0.00227	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—MDM2—muscle cancer	8.76e-05	0.000587	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.58e-05	0.000575	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—FH—muscle cancer	8.31e-05	0.000557	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MDM2—muscle cancer	8.3e-05	0.000556	CbGpPWpGaD
Vismodegib—ALB—Metabolism—FH—muscle cancer	8.27e-05	0.000554	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—MED12—muscle cancer	7.57e-05	0.000507	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—FH—muscle cancer	7.42e-05	0.000497	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	7.25e-05	0.000486	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—FH—muscle cancer	7.24e-05	0.000485	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	6.99e-05	0.000468	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ENO2—muscle cancer	6.9e-05	0.000462	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IGF2—muscle cancer	6.87e-05	0.00046	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—FH—muscle cancer	6.77e-05	0.000453	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—VEGFA—muscle cancer	6.65e-05	0.000446	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—VEGFA—muscle cancer	6.31e-05	0.000422	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	5.59e-05	0.000375	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.5e-05	0.000369	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—muscle cancer	5.03e-05	0.000337	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—muscle cancer	4.76e-05	0.000319	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—MED12—muscle cancer	4.7e-05	0.000315	CbGpPWpGaD
Vismodegib—ALB—Metabolism—MED12—muscle cancer	4.67e-05	0.000313	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—FH—muscle cancer	4.46e-05	0.000299	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ENO2—muscle cancer	4.28e-05	0.000287	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ENO2—muscle cancer	4.26e-05	0.000285	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—MED12—muscle cancer	4.19e-05	0.000281	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.16e-05	0.000279	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—MED12—muscle cancer	4.09e-05	0.000274	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—MED12—muscle cancer	3.82e-05	0.000256	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ENO2—muscle cancer	3.82e-05	0.000256	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ENO2—muscle cancer	3.73e-05	0.00025	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ENO2—muscle cancer	3.49e-05	0.000234	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.35e-05	0.000224	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.33e-05	0.000223	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.99e-05	0.0002	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFA—muscle cancer	2.88e-05	0.000193	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.73e-05	0.000183	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MED12—muscle cancer	2.52e-05	0.000169	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTGS2—muscle cancer	2.4e-05	0.000161	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ENO2—muscle cancer	2.3e-05	0.000154	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—muscle cancer	2.18e-05	0.000146	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTGS2—muscle cancer	1.49e-05	9.99e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTGS2—muscle cancer	1.48e-05	9.94e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTGS2—muscle cancer	1.33e-05	8.92e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTGS2—muscle cancer	1.3e-05	8.71e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTGS2—muscle cancer	1.21e-05	8.13e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTGS2—muscle cancer	8.01e-06	5.36e-05	CbGpPWpGaD
